Reyes M,
Rojas-Alcayaga G, Maturana A, Aitken
JP, Rojas C, Ortega AV. Increased nuclear β-catenin expression in oral
potentially malignant lesions: A marker of epithelial dysplasia. Med Oral Patol Oral Cir Bucal. 2015 Sep
1;20 (5):e540-6.
doi:10.4317/medoral.20341
http://dx.doi.org/doi:10.4317/medoral.20341
|
1. Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007;36:575-80. |
|
|
|
|
|
2. Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E. Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement.
J Oral Pathol Med.
2008;37:127-33. |
|
|
|
|
|
3. Reichart PA, Philipsen HP. Oral
erythroplakia-a review.
Oral Oncol. 2005;41:551-61. |
|
|
|
|
|
4. Neville BW, Day TA. Oral cancer
and precancerous lesions.
CA Cancer J Clin.
2002;52:195-215. |
|
|
|
|
|
5.
Hall GL, Shaw RJ, Field EA, Rogers SN, Sutton DN, Woolgar
JA, et al. p16 Promoter methylation
is a potential predictor
of malignant transformation
in oral epithelial dysplasia.
Cancer Epidemiol Biomarkers Prev.
2008;17:2174-9. |
|
|
|
|
|
6. Krutchkoff DJ, Eisenberg E,
Anderson C. Dysplasia of oral mucosa: a unified approach to proper evaluation.
Mod Pathol. 1991;4:113-9. |
|
|
|
|
|
7. Lippman SM, Lee JS, Lotan R, Hittelman W, Wargovich MJ, Hong
WK. Biomarkers as intermediate
end points in chemoprevention trials. J Natl Cancer Inst.
1990;82:555-60. |
|
|
|
|
|
8. Kushner J, Bradley G, Jordan
RC. Patterns of p53 and Ki-67 protein
expression in epithelial dysplasia from the floor of the mouth. J Pathol. 1997;183:418-23. |
|
|
|
|
|
9. Zoeller J, Flentje M, Sinn P, Born IA. Evaluation of AgNOR and Ki-67 antigen as cell kinetic parameters in oral dysplasias
and carcinomas. Anal Cell Pathol.
1994;7:77-88. |
|
|
|
|
|
10. Polanska H, Raudenska M, Gumulec J, Sztalmachova M, Adam
V, Kizek R, et al. Clinical
significance of head and neck
squamous cell cancer biomarkers. Oral Oncol. 2014;50:168-77. |
|
|
|
|
|
11. Zidar N, Gale N, Cor A, Kambic V. Expression of Ki-67 antigen and proliferative cell nuclear antigen in benign and malignant epithelial lesions of the larynx. J Laryngol Otol. 1996;110:440-5. |
|
|
|
|
|
12. Nusse R, Varmus HE. Many tumors induced
by the mouse mammary tumor virus contain a provirus integrated in the same region
of the host genome. Cell. 1982;31:99-109. |
|
|
|
|
|
13. KŸhl M, Sheldahl LC, Park M,
Miller JR, Moon RT. The Wnt/Ca2+
pathway: a new vertebrate
Wnt signaling pathway takes shape. Trends Genet. 2000;16:279-83. |
|
|
|
|
|
14.
Dale TC. Signal transduction
by the Wnt family of ligands. Biochem J.
1998;329:209-23. |
|
|
|
|
|
15. Munemitsu S, Albert I, Souza B, Rubinfeld
B, Polakis P. Regulation
of intracellular beta-catenin
levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad
Sci U S A. 1995;92:3046-50. |
|
|
|
|
|
16. Orford K, Crockett C, Jensen
JP, Weissman AM, Byers
SW. Serine phosphorylation-regulated
ubiquitination and degradation
of beta-catenin. J Biol Chem. 1997;272:24735-8. |
|
|
|
|
|
17. Takahashi-Yanaga F, Sasaguri T.
The Wnt/beta-catenin signaling pathway as a target in drug discovery. J Pharmacol Sci. 2007;104:293-302. |
|
|
|
|
|
18.
Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434:843-50. |
|
|
|
|
|
19.
Ochoa-Hernandez AB, Juarez-Vazquez
CI, Rosales-Reynoso MA, Barros-Nunez P. [WNT-beta-catenin signaling pathway and its relationship with cancer]. Cir Cir. 2012;80:389-98. |
|
|
|
|
|
20. Luu HH, Zhang R, Haydon RC, Rayburn E, Kang Q, Si W, et al.
Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug
Targets. 2004;4:653-71. |
|
|
|
|
|
21. Gonzalez-Moles MA, Ruiz-Avila
I, Gil-Montoya JA, Esteban F, Bravo M. Analysis of
Ki-67 expression in oral squamous
cell carcinoma: why Ki-67
is not a prognostic indicator. Oral Oncol. 2010;46:525-30. |
|
|
|
|
|
22. Warnakulasuriya KA, MacDonald
DG. Epithelial cell kinetics in oral leukoplakia. J
Oral Pathol Med.
1995;24:165-9. |
|
|
|
|
|
23. Shah NG, Trivedi TI, Tankshali RA, Goswami JA, Shah JS, Jetly DH, et al.
Molecular alterations in oral carcinogenesis:
significant risk predictors in malignant transformation and tumor progression.
Int J Biol Markers. 2007;22:132-43. |
|
|
|
|
|
24. Bjarnason GA, Jordan RC, Sothern RB. Circadian variation in the expression of cell-cycle proteins in human oral epithelium.
Am J Pathol. 1999;154:613-22. |
|
|
|
|
|
25. Saito T, Nakajima T, Mogi K. Immunohistochemical analysis of cell cycle-associated proteins p16, pRb, p53, p27 and Ki-67 in oral cancer
and precancer with special reference to verrucous carcinomas. J Oral
Pathol Med.
1999;28:226-32. |
|
|
|
|
|
26. Mimica M, Tomic S, Kardum G, Hofman ID, Kaliterna V, Pejkovic L. Ki-67 quantitative evaluation as a marker of
cervical intraepithelial neoplasia and human papillomavirus infection. Int J Gynecol Cancer. 2010;20:116-9. |
|
|
|
|
|
27. Cambruzzi E, Zettler CG,
Alexandre CO. Expression of Ki-67 and squamous intraepithelial lesions are related with HPV in endocervical
adenocarcinoma. Pathol Oncol
Res. 2005;11:114-20. |
|
|
|
|
|
28. Yap AS, Brieher WM, Gumbiner BM. Molecular and functional
analysis of cadherin-based
adherens junctions. Annu Rev Cell
Dev Biol. 1997;13:119-46. |
|
|
|
|
|
29.
Johnson ML, Rajamannan N. Diseases
of Wnt signaling. Rev Endocr Metab
Disord. 2006;7:41-9. |
|
|
|
|
|
30.
Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev
Biol. 2004;20:781-810. |
|
|
|
|
|
31. Luo J, Chen J, Deng ZL, Luo X, Song WX, Sharff KA, et al. Wnt signaling and human diseases: what are the therapeutic implications?. Lab Invest. 2007;87:97-103. |
|
|
|
|
|
32.
Lo Muzio L, Lo Russo L, Falaschini S, Ciavarella D, Pentenero M, Arduino P, et al.
beta- and gamma-catenin expression
in oral dysplasia. Oral Oncol.
2009;45:501-4. |
|
|
|
|
|
33. Laxmidevi LB, Angadi PV, Pillai RK, Chandreshekar C. Aberrant beta-catenin expression in the histologic differentiation of
oral squamous cell
carcinoma and verrucous carcinoma: an immunohistochemical study. J Oral Sci.
2010;52:633-40. |
|
|
|
|
|
34.
Williams HK, Sanders DS, Jankowski JA, Landini G, Brown AM. Expression
of cadherins and catenins
in oral epithelial dysplasia
and squamous cell
carcinoma. J Oral Pathol Med.
1998;27:308-17. |
|
|
|
|
|
35. Bankfalvi A, Krassort M, Vegh A, Felszeghy E, Piffko J. Deranged expression of the E-cadherin/beta-catenin complex and the epidermal growth factor
receptor in the clinical evolution and progression of
oral squamous cell
carcinomas. J Oral Pathol Med.
2002;31:450-7. |
|
|
|
|
|
36. Bankfalvi A, Krassort M, Buchwalow IB, Vegh A, Felszeghy E, Piffko J. Gains and losses of adhesion molecules (CD44, E-cadherin, and beta-catenin) during oral carcinogenesis and tumour progression. J Pathol. 2002;198:343-51. |
|
|
|
|
|
37. Yu Z, Weinberger PM, Provost E, Haffty BG, Sasaki C, Joe J, et al. beta-Catenin functions mainly as an adhesion molecule in patients with squamous cell cancer of the head and neck. Clin Cancer
Res. 2005;11:2471-7. |
|
|
|
|
|
38. Gasparoni A, Chaves A, Fonzi L,
Johnson GK, Schneider GB, Squier CA. Subcellular localization of
beta-catenin in malignant
cell lines and squamous cell carcinomas of the oral cavity. J Oral Pathol Med. 2002;31:385-94. |
|
|
|
|
|
39. Bagutti C, Speight PM, Watt FM.
Comparison of integrin, cadherin, and catenin expression in squamous cell carcinomas of the oral cavity. J Pathol.
1998;186:8-16. |
|
|
|
|
|
40.
Sato K, Okazaki Y, Tonogi
M, Tanaka Y, Yamane GY. Expression of beta-catenin in rat oral epithelial dysplasia induced by 4-nitroquinoline 1-oxide. Oral Oncol.
2002;38:772-8. |
|
|
|
|
|
41. Ishida K, Ito S, Wada N, Deguchi H, Hata T, Hosoda M, et al.
Nuclear localization of beta-catenin
involved in precancerous change in oral leukoplakia. Mol
Cancer. 2007;6:62. |
|